To evaluate tumor-specific T cell responses, the same groups of mice were bled 10 days after the first treatment and the amount of CD8+ tumor-specific T cells in the blood was quantified using two different assays to identify B16-F10 tumor-specific T cells. This evidence concerns the gene CD8A and neoplasm.